Caroline Robert
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Immunology top 0.05%
- Immunotherapy and Immune Responses
Papers in
- Oncology 398
- Cancer Immunotherapy and Biomarkers 278
- Cutaneous Melanoma Detection and Management 138
- Dermatology 63
- Chemotherapy-related skin toxicity 39
- Skin Protection and Aging 16
- Co-authors
- James Larkin (41 shared papers)Dirk Schadendorf (83 shared papers)Alexander M.M. Eggermont (69 shared papers)Frank Stephen Hodi (24 shared papers)Franck Carbonnel (20 shared papers)Christine Mateus (67 shared papers)John B.A.G. Haanen (12 shared papers)Omid Hamid (30 shared papers)
- Journals
- Annals of Oncology (105 papers)European Journal of Cancer (100 papers)Journal of Clinical Oncology (34 papers)The Lancet Oncology (33 papers)Clinical Cancer Research (26 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
Caroline Robert
667 papers receiving 125.4k citations
Caroline Robert's Hit Papers
Peers
Comparison fields: 5 of 178
- Oncology 73.4k
- Immunology 10.1k
- Dermatology 3.8k
- Molecular Biology 27.9k
- Cancer Research 4.4k
Countries citing papers authored by Caroline Robert
This map shows the geographic impact of Caroline Robert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Robert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Robert more than expected).
Fields of papers citing papers by Caroline Robert
This network shows the impact of papers produced by Caroline Robert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Robert. The network helps show where Caroline Robert may publish in the future.
Co-authors
The 25 scholars most cited alongside Caroline Robert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 698 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Hit paper breakdown → | 2010 | 12673 |
| 2 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Hit paper breakdown → | 2011 | 6392 |
| 3 | PD-1 blockade induces responses by inhibiting adaptive immune resistance Hit paper breakdown → | 2014 | 5584 |
| 4 | Pembrolizumab versus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2015 | 4911 |
| 5 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation Hit paper breakdown → | 2014 | 4689 |
| 6 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Hit paper breakdown → | 2011 | 3745 |
| 7 | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Hit paper breakdown → | 2013 | 2930 |
| 8 | Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota Hit paper breakdown → | 2015 | 2922 |
| 9 | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Hit paper breakdown → | 2015 | 2365 |
| 10 | Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Hit paper breakdown → | 2014 | 2176 |
| 11 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 1963 |
| 12 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Hit paper breakdown → | 2012 | 1821 |
| 13 | Immune-related adverse events with immune checkpoint blockade: a comprehensive review Hit paper breakdown → | 2016 | 1796 |
| 14 | Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma Hit paper breakdown → | 2015 | 1740 |
| 15 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Hit paper breakdown → | 2014 | 1559 |
| 16 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Hit paper breakdown → | 2014 | 1539 |
| 17 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Hit paper breakdown → | 2018 | 1513 |
| 18 | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Hit paper breakdown → | 2015 | 1348 |
| 19 | A decade of immune-checkpoint inhibitors in cancer therapy Hit paper breakdown → | 2020 | 1296 |
| 20 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1224 |
About Caroline Robert
Caroline Robert is a scholar working on Oncology, Dermatology, Molecular Biology, Immunology and Epidemiology, having authored 698 papers that have together received 128.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (278 papers), Melanoma and MAPK Pathways (153 papers), Cutaneous Melanoma Detection and Management (138 papers), Chemotherapy-related skin toxicity (39 papers), Nonmelanoma Skin Cancer Studies (28 papers), Immunotherapy and Immune Responses (22 papers), Skin Protection and Aging (16 papers) and Hedgehog Signaling Pathway Studies (13 papers). The work is most often cited by research in Oncology (73.4k citations), Immunology (10.1k citations), Dermatology (3.8k citations), Molecular Biology (27.9k citations) and Cancer Research (4.4k citations). Caroline Robert has collaborated with scholars based in France, United States and Germany. Frequent co-authors include James Larkin, Dirk Schadendorf, Alexander M.M. Eggermont, Frank Stephen Hodi, Franck Carbonnel, Christine Mateus, John B.A.G. Haanen, Omid Hamid, Jedd D. Wolchok and Reinhard Dummer. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.